The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
NCT ID: NCT04351347
Last Updated: 2021-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2/PHASE3
300 participants
INTERVENTIONAL
2020-06-16
2030-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ivermectin in Treatment of COVID-19
NCT04445311
Efficacy of Ivermectin in Outpatients With Non-severe COVID-19
NCT04834115
Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic
NCT04668469
Ivermectin In Treatment of COVID 19 Patients
NCT04425707
Ivermectin Nasal Spray for COVID19 Patients
NCT04510233
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ivermectin
Ivermectin alone in larger doses
Ivermectin
ivermectin
Standard treatment
Standard of care treatment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ivermectin
ivermectin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
Ass. Prof. Tropical Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
sherief Abd-Elsalam, Ass. Prof.
Role: PRINCIPAL_INVESTIGATOR
Tanta University - Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sherief Abd-Elsalam
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ivermecin covid
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.